---
document_datetime: 2023-09-21 20:51:04
document_pages: 17
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/beromun-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: beromun-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 9.9873519
conversion_datetime: 2025-12-25 10:38:47.479995
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Beromun

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0057              | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product | 09/12/2021                          |                                             | Annex II                         |           |
| IAIN/0056            | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier                                         | 23/06/2021                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                     |            |     |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/2850/ 202008 | Periodic Safety Update EU Single assessment - tasonermin                                                                                                                                                                                       | 09/04/2021 | n/a | PRAC Recommendation - maintenance |
| IAIN/0055          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 27/01/2021 | n/a |                                   |
| II/0051            | B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                                         | 10/12/2020 | n/a |                                   |
| II/0050            | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                          | 10/12/2020 | n/a |                                   |
| IAIN/0052          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 30/10/2020 | n/a |                                   |
| IAIN/0049          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 08/05/2020 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| IAIN/0048   | - Change to importer, batch release and quality control testing of the FP - or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 18/03/2020   | 23/07/2021   | Annex II and PL   | B.II.b.2.c.1 arrangements Replacement   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|-----------------------------------------|
| IAIN/0047/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 12/03/2020   | n/a          |                   |                                         |
| IAIN/0046   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 10/01/2020   | n/a          |                   |                                         |

<div style=\"page-break-after: always\"></div>

|             | a medicinal product. (PMF 2nd step procedure) - of an updated/amended PMF when changes not affect the properties of the FP                                                                                                                                                                                                                                                                   |            |     | of Inclusion do   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| IAIN/0045   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                               | 03/12/2019 | n/a |                   |
| IB/0043     | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                   | 08/11/2019 | n/a |                   |
| IAIN/0042/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 19/07/2019 | n/a |                   |
| IAIN/0041   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                               | 13/06/2019 | n/a |                   |

<div style=\"page-break-after: always\"></div>

| T/0040             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 17/07/2018   | 23/08/2018   | SmPC, Labelling and PL   |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------------------------|
| IAIN/0039/G        | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes | 04/07/2018   | n/a          |                          |                                   |
| PSUSA/2850/ 201708 | Periodic Safety Update EU Single assessment - tasonermin                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 12/04/2018   | n/a          |                          | PRAC Recommendation - maintenance |
| IAIN/0037/G        | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes | 25/08/2017   | n/a          |                          |                                   |

<div style=\"page-break-after: always\"></div>

|             | do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                        |                   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------|
| IB/0035     | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                   | 03/07/2017 | n/a        |                        |                   |
| IAIN/0036/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes properties of the FP | 16/05/2017 | n/a        |                        | do not affect the |
| IAIN/0034   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                 | 27/02/2017 | n/a        |                        |                   |
| IB/0033     | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 14/01/2017 | 03/10/2017 | SmPC and PL            |                   |
| IB/0032     | B.II.a.6 - Deletion of the solvent/diluent container from the pack                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 27/09/2016 | 03/10/2017 | SmPC, Labelling and PL |                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IAIN/0031/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 28/07/2016   | n/a   |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
|               | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP |              |       |

<div style=\"page-break-after: always\"></div>

| IAIN/0030/G        | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP   | 03/08/2015   | n/a   |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| PSUSA/2850/ 201408 | Periodic Safety Update EU Single assessment - tasonermin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 12/03/2015   | n/a   | PRAC Recommendation - maintenance |
| IB/0029/G          | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 11/02/2015   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

|         | finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation   |            |            |                           |                                                                                                                     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------|---------------------------------------------------------------------------------------------------------------------|
| IG/0432 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                         | 16/04/2014 | n/a        |                           |                                                                                                                     |
| N/0026  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                        | 06/12/2013 | 03/10/2017 | PL                        |                                                                                                                     |
| II/0025 | Change in source of an excipient or reagent with TSE risk. B.II.c.3.b - Change in source of an excipient or reagent with TSE risk - Change or introduction of a TSE risk material or replacement of a TSE risk material from a different TSE risk material, not covered by a TSE certificate of suitability                                                                                                                                             | 21/11/2013 | n/a        |                           |                                                                                                                     |
| II/0024 | Update of section 4.8 of the SmPC to add the adverse reaction peripheral arterial occlusive disease                                                                                                                                                                                                                                                                                                                                                     | 15/11/2012 | 20/11/2013 | SmPC, Annex II, Labelling | Late onset of peripheral arterial occlusive disease (PAOD) of the lower limbs has been reported in patients several |

<div style=\"page-break-after: always\"></div>

|           | with a frequency uncommon at the request from the CHMP following the assessment of PSUR 10. The package Leaflet is updated accordingly. The MAH also took the opportunity to update the product information in line with the latest QRD template (version 8.1) and to update the list of local representatives in the Package leaflet. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH   |            |     | and PL   | years after ILP, predominantly in patients presenting with established cardiovascular risk factors, or who had undergone additional irradiation therapy of the concerned limb.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0211   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 05/09/2012 | n/a |          |                                                                                                                                                                                  |
| II/0022/G | This was an application for a group of variations. Change in the specifications for the finished product. Change to in-process limits applied during the manufacture of the finished product. Change in test procedure for the finished product. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change                                                                                                                       | 19/04/2012 | n/a |          |                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|           | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0020   | Update of section 4.8 of the Summary of Product Characteristics (SmPC) further to a review of the methodology applied for the estimation of frequency of adverse reactions and extension of the safety dataset. Changes were also proposed to bring this section in line with the EU SmPC guideline. The Package leaflet has been updated accordingly. The Marketing Authorisation Holder (MAH) also proposed updates throughout the product information in line with the QRD template version 7.3.1 and the EU Guideline on Excipients including addition of information on the influence on human fertility to section 4.6 of the SmPC, a correction with regard to sodium chloride being an ingredient of the solvent and a warning in section 4.4 that the container of this medicinal product contains latex rubber. Editorial changes were also proposed throughout the product information. The MAH also took the opportunity to update the list of local representatives in the package leaflet. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- | 23/06/2011 | 27/07/2011 | SmPC, Labelling and PL | In order to allow a more robust estimation of frequency categories, the reference study data set was extended by adding three further studies in non-approved indication. The study design, doses, treatment duration and patient population in these studies were considered by the MAH to be comparable to the studies in the approved indication soft tissue sarcoma, which previously served as the basis for estimation of frequency categories. Reports of all studies had been provided in the original Marketing Authorisation Application for Beromun. Four new undesirable effects were identified which, however, in their underlying genesis did not fundamentally differ from the already known side effects (Abdominal pain upper, gastritis erosive, blood creatinine increased and pulmonary oedema). The extension of the reference study data as well as the change in methodology applied to frequency calculation resulted in a change in the frequency category for six previously listed undesirable effects. As a result of the changes described above, a complete revision and restructuring following the recommendations of the EU SmPC guideline was proposed for this section. |
| IB/0021/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 01/07/2011 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|           | B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure B.II.e.3.b - Change in test procedure for the immediate packaging of the finished product - Other changes to a test procedure (including replacement or addition) B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information   |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0019/G | This was an application for a group of variations. B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                                                                                                                                                                                                                                                                              | 10/06/2011 | n/a |

<div style=\"page-break-after: always\"></div>

|           | procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
| II/0018/G | This was an application for a group of variations. - Multiple changes to the manufacturing process of the active substance during both fermentation and purification aiming at optimizing the manufacturing process, changes to in-process tests and limits applied during the manufacture of the active substance - Multiple changes in test procedure, specification parameters and limits applied to cell banks, raw materials, biomass and active substance B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation | 19/05/2011 | 19/05/2011 |

<div style=\"page-break-after: always\"></div>

| applied during the manufacture variation B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| B.I.b.2.a - Change in starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change in starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change in starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change in starting material/reagent/intermediate changes to an approved B.I.b.2.d - Change in starting material/reagent/intermediate (replacement) to a biological/immunological/ immunochemical test biological reagent for B.I.b.2.e - Change in starting material/reagent/intermediate changes to a test procedure or addition) for the material/intermediate B.I.d.1.a.4 - Stability period/storage period re-test period/storage data B.III.2.a.2 - Change non Pharmacopoeial Ph. Eur. or with a national   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IA/0017   | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.) IA_05_Change in the name and/or address of a manufacturer of the finished product   | 27/03/2009   | n/a        | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0015    | Renewal of the marketing authorisation.                                                                                                                                                | 22/01/2009   | 25/03/2009 | SmPC, Annex II, Labelling and PL | Based on the CHMP review of the available information and on the basis of the re-evaluation of the benefit risk balance, the CHMP is of the opinion that the quality, safety and efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considered that the benefit risk profile of Beromun continues to the favourable. The CHMP is also of the opinion that the renewal can be granted with unlimited validity. PSURs will now be submitted every 3 years. |
| II/0013   | Changes to the specifications for the active substance. Change(s) to the test method(s) and/or specifications for the active substance                                                 | 25/09/2008   | 02/10/2008 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0012   | Change(s) to the test method(s) and/or specifications for the active substance                                                                                                         | 28/06/2006   | 03/07/2006 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0011   | Quality changes                                                                                                                                                                        | 18/11/2004   | 22/11/2004 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| R/0010    | Renewal of the marketing authorisation.                                                                                                                                                | 26/02/2004   | 17/06/2004 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0008   | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                       | 25/09/2003   | 27/01/2004 | SmPC and PL                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| II/0009   | Update of or change(s) to the pharmaceutical documentation                                                                                 | 17/12/2003   | 23/12/2003   |                 |                    |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------|--------------------|
| II/0006   | Change(s) to the test method(s) and/or specifications for the active substance Change(s) to the test method(s) and/or the finished product | 23/01/2003   | 28/01/2003   |                 | specifications for |
| N/0007    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                           | 15/12/2002   | 16/12/2002   | PL              |                    |
| II/0005   | Update of Summary of Product Characteristics and Package Leaflet                                                                           | 23/08/2001   | 28/01/2002   | SmPC and PL     |                    |
| I/0004    | 12_Minor change of manufacturing process of the active substance                                                                           | 16/11/2000   | n/a          |                 |                    |
| I/0002    | 11_Change in or addition of manufacturer(s) of active substance                                                                            | 25/05/1999   | 29/07/1999   | Annex II and PL |                    |
| I/0001    | 01_Change in the name of a manufacturer of the medicinal product                                                                           | 25/05/1999   | 29/07/1999   | Annex II and PL |                    |
| N/0003    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                           | 25/05/1999   | 29/07/1999   | PL              |                    |